QualityStocks

[QualityStocks]

QualityStocksNewsBreaks – Pressure BioSciences Inc.’s (PBIO) Proprietary PCT Platform Demonstrates Ability to Discover Cancer Biomarkers in Independent Research

Pressure BioSciences’ (OTCQB: PBIO) pressure cycling technology (“PCT”) platform was recently the subject of independent research carried out by Chinese and Australian scientists in which the platform demonstrated its proficiency in processing of preserved (“FFPE”) and fresh frozen biopsy tissue samples for the discovery of cancer biomarkers (http://ibn.fm/DfmC7). An article discussing the company reads, “According to Pressure BioSciences president and CEO Richard T. Schumacher, over one billion archival tissue samples exist in pathology and other laboratories across the world. Millions of additional samples are processed and stored every single year. These samples contain an abundance of information that could be key to the discovery of new cancer biomarkers, development of new cancer diagnostics, and release of new treatments and prevention measures, Schumacher concluded. . . . ‘We believe that our PCT platform is establishing itself as the method of choice for the superior extraction of potential biomarkers and their presentation for the effective proteomic analyses that will propel the growth of this huge market,’ Pressure BioSciences’ director of marketing and sales Roxana McCloskey added.”

To view the full article, visit http://ibn.fm/V1xSI

About Pressure BioSciences Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences industry. The company’s products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions (e.g., cell lysis, biomolecule extraction). PBIO’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of its pressure-based technologies in the following areas: (1) the use of its recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of its recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. For more information, visit the company’s website at www.PressureBiosciences.com.

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO